Anaptysbio (ANAB) Receivables (2016 - 2026)

Anaptysbio (ANAB) has 10 years of Receivables data on file, last reported at $25.7 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 43.97% year-over-year to $25.7 million; the trailing twelve-month figure through Mar 2026 stood at $25.7 million (up 43.97% YoY), and the FY2025 full-year result was $33.8 million, down 16.96% from the prior year.
• Receivables for Q1 2026 stood at $25.7 million, down from $33.8 million in the prior quarter.
• Across five years, Receivables topped out at $75.7 million in Q3 2025 and bottomed at $921000.0 in Q1 2022.
• The 5-year median for Receivables is $7.1 million (2024), against an average of $15.5 million.
• The widest annual swing landed in 2022, when Receivables dropped 26.14%; it then jumped 520.62% in 2025.
• A 5-year view of Receivables shows it stood at $1.4 million in 2022, then jumped by 382.8% to $6.9 million in 2023, then jumped by 495.02% to $40.8 million in 2024, then retreated by 16.96% to $33.8 million in 2025, then decreased by 23.94% to $25.7 million in 2026.
• The last three Receivables figures came in at $25.7 million (Q1 2026), $33.8 million (Q4 2025), and $75.7 million (Q3 2025), per Business Quant data.

Peer Comparison